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a b s t r a c t
Objectives: Hyper-inﬂammation caused by COVID-19 may be mediated by mast cell activation (MCA)
which has also been hypothesized to cause Long-COVID (LC) symptoms. We determined prevalence/severity of MCA symptoms in LC.
Methods: Adults in LC-focused Facebook support groups were recruited for online assessment of symptoms before and after COVID-19. Questions included presence and severity of known MCA and LC symptoms and validated assessments of fatigue and quality of life. General population controls and mast cell
activation syndrome (MCAS) patients were recruited for comparison if they were ≥18 years of age and
never had overt COVID-19 symptoms.
Results: There were 136 LC subjects (89.7% females, age 46.9 ±12.9 years), 136 controls (65.4% females,
age 49.2 ±15.5), and 80 MCAS patients (85.0% females, age 47.7 ±16.4). Pre-COVID-19 LC subjects and
controls had virtually identical MCA symptom and severity analysis. Post-COVID-19 LC subjects and MCAS
patients prior to treatment had virtually identical MCA symptom and severity analysis.
Conclusions: MCA symptoms were increased in LC and mimicked the symptoms and severity reported
by patients who have MCAS. Increased activation of aberrant mast cells induced by SARS-CoV-2 infection
by various mechanisms may underlie part of the pathophysiology of LC, possibly suggesting routes to
effective therapy.
© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)

Abbreviations: BMI, body mass index; CI, conﬁdence intervals; MC, mast cell;
MCA, mast cell activation; MCs, mast cells; MCAS, mast cell activation syndrome;
MCMRS, mast cell mediator release syndrome; N, number; NS, not signiﬁcant; OR,
odds ratio; SD, standard deviation.
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Introduction
The COVID-19 pandemic has spread throughout the world, with
calamitous outcomes for some of those acutely infected and for
those who struggle with Long-COVID (LC), also known as LongHaul COVID and post-acute sequelae of COVID-19 (Yong, 2021).
Several COVID-19 outcome studies have determined that longstanding, often disabling symptoms are common (Davis et al., 2021,
FAIR Health White Paper, 2021, Yong, 2021). The largest studies determined that LC symptoms occurred in: 1) 23.2% overall,
and in 50% of those who were hospitalized, in 1.9 million Americans; (FAIR Health White Paper, 2021) 2) 44.2% in 1142 Spaniards;
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(Fernández-de-Las-Peñas et al., 2021) and 3) 47.1% of 2649 Russians (Munblit et al., 2021). LC has been described as “a mysterious mix of symptoms with no clear pattern” by one expert from
The Centers for Disease Control and Prevention (Stulpin, 2021).
The hyper-inﬂammatory responses seen in acute COVID-19
infection and in LC have been hypothesized to be mediated
in part by mast cell activation (MCA) (Kritas et al., 2020,
Theoharides and Conti, 2020, Theoharides, 2021). We hypothesized
that baseline/pre-existing mast cell activation syndrome (MCAS,
whether clinically recognized prior to COVID-19 infection or not)
might explain hyper-inﬂammatory responses in acute COVID-19 infection and LC (Afrin et al., 2020a). In MCAS, unregulated release
of chemical mediators produces a remarkable multitude of symptoms, many of which are suffered by LC patients (Afrin et al.,
2017, 2016a, 2020, 2016b). First reported in 2007, MCAS is a multifactorial, usually somatically polygenic chronic multisystem disorder with inﬂammatory and allergic themes and has an estimated
prevalence of 17% (Afrin et al., 2020b, Molderings et al., 2007,
Molderings et al., 2013). Patients with MCAS often remain undiagnosed and symptomatic for decades (Afrin et al., 2017). The natural history of MCAS not uncommonly sees signiﬁcant escalation
of its baseline level of dysfunctional mast cell behavior, for long or
indeﬁnite periods, shortly (days to a few months) following major physical or psychological stressors, possibly due to induction of
additional somatic mutations by stressor-induced cytokine storms
(Afrin et al., 2020b).
We examined the prevalence and severity of MCA symptoms in
LC.

and the oﬃces of the lead investigator (LBW). The MCAS patients
were diagnosed in the last two years by the lead investigator and
consented to ﬁlling out the questionnaire. The controls and the
MCAS patients never had symptoms of an acute COVID-19 infection. The consent for the control group stated that they could volunteer even if they had chronic symptoms, conditions, or diseases.
In this manner we did not exclude MCA symptoms in this group.
The only other exclusion criteria for all groups were age <18 and
current pregnancy (or pregnancy during COVID-19). General population control group was recruited through an Intranet posting
and handouts advertising the study (Appendix 2). The MCAS patients diagnosed in the last two years by the lead investigator were
mailed a cover letter explaining the study, and the consent form
and questionnaires were enclosed in the packet (Appendix 3). The
IRB committee gave their permission for these activities.
The diagnosis of MCAS in the MCAS patient group was based
on the following Consensus-2 diagnostic criteria, i.e., typical symptoms of MCA in 5 or more organ systems plus both of the following
criteria: at least one or more elevated mast cell (MC) mediator(s)
and clinical improvement with MC-directed therapy (Afrin et al.,
2020b). If intestinal biopsies had been performed in the work-up,
the MC density had to be ≥20 per high power ﬁeld (HPF). We
modiﬁed these Consensus-2 criteria to require 5 systems in place
of the previous 2 or more systems in order to reduce potential
overdiagnosis of MCAS. The MC mediator measurements included:
1) plasma prostaglandin D2, histamine, and heparin; 2) serum
tryptase and chromogranin A; and 3) 24-hour urine prostaglandin
11-β -PGF2α , N-methylhistamine, and leukotriene E4. To help conﬁrm a clinical diagnosis and the severity of MCA, the latest version
of the mast cell mediator release syndrome (MCMRS) score was
employed, which includes symptoms and severity scores of symptoms seen in MCA disorders (Appendix 4) (Molderings et al., 2006,
Afrin et al, 2016a, Theoharides et al, 2019, Weinstock et al., 2021,
Weinstock et al., 2020). The MCMRS score also includes points for
abnormal laboratory, radiographic, and biopsy ﬁndings, but these
were not measured in the LC or general control group subjects. A
score of ≥14 is consistent with a MC mediator release syndrome
which is found in MCAS, mastocytosis, MC leukemia, and other
disorders of MC activation (Appendix 4). The ﬁnal requirement to
diagnose MCAS was to exclude other appropriate disorders in the
differential diagnosis.
The questions in the MCMRS were used to construct the questionnaire that was administered to all 3 groups in the study. Additional questions were added to this that assessed known LC symptoms, FAS, and QOL (Appendix 1A and 1B). The MCMRS symptoms
were assessed for LC participants and controls, but laboratory and
biopsy ﬁndings were not measured. The MCMRS questionnaire was
used in all subjects in three ways: total number of MCMRS symptoms, cumulative MCMRS severity score which was the total of all
symptom severity scores, and MCMRS system count which was the
total number of body systems that were affected. The total number
of MC and LC symptoms was also tabulated.
The primary aims were to determine whether prevalence and
severity of MCA symptoms in LC were: 1) starting from a baseline similar to healthy controls; 2) signiﬁcantly higher after COVID19; and 3) ultimately reaching a level that resembled MCAS patients. After scores were calculated for the MCMRS, each score and
symptom underwent three analyses. First, independent samples ttests or chi-square tests of independence compared LC group’s preCOVID-19 mean scores or symptom prevalence to those of controls.
Second, paired samples t-tests or McNemar’s tests were used to
determine whether the LC group’s mean scores or symptom prevalence were signiﬁcantly higher after COVID-19. Third, independent
samples t-tests or chi-square tests were again used to compare
post-COVID scores/prevalence to those of MCAS patients prior to
MCAS treatment. A value of p ≤ 0.05 was considered statistically

Methods
The study was approved by the Missouri Baptist Medical Center
Investigational Review Board in St. Louis, Missouri. Data collection
started in October 2020 and ended May 2021. LC-focused Facebook
group organizers were contacted to allow us to advertise an online study on their website promoting an investigation of symptoms present before and after COVID-19 infection. No other descriptors were provided that might bias recruitment. Questions included presence/severity of known symptoms of MCA (Afrin et al.,
2017) and LC symptoms (Davis et al., 2021, FAIR Health White Paper, 2021, Yong, 2021) and validated assessments of fatigue and
quality of life (QOL) (Balestroni and Bertolotti, 2012, De Vries et al.,
2003, Hendriks et al., 2018). The fatigue assessments scale (FAS)
was calculated from a 10-item questionnaire with 5 questions for
physical fatigue and 5 questions for mental fatigue. These ten FAS
questions were ranked from 1 to 5: scores 10 to 21: no fatigue;
scores 22 to 34: substantial fatigue; and scores 35 to 50: extreme
fatigue. The self-rated overall general health scores or QOL scores
were ranked on a scale from 0 to 100 where 0 was the worst
imaginable health and 100 was the best imaginable health. The LC
subjects ﬁlled out their pre-COVID-19 questionnaire by recall; at
the same time, they ﬁlled out their identical post-COVID-19 questionnaire. The MCAS patients were asked to answer the questionnaire by recall of their original symptoms and severity prior to
treatment. The questions in the control and MCAS patient questionnaires were identical to those for the COVID-19 patients. The
LC group ﬁlled out the two questionnaires which were titled: 1)
BEFORE THE COVID INFECTION QUESTIONS and 2) AFTER THE
COVID INFECTION QUESTIONS (Appendix 1A and 1B). In this article, we designate the Long-COVID participants in the following
manner: 1) pre-COVID-LC participants refers to the LC groups’
characteristics and recall of symptoms prior to the acute infection
with COVID-19; and 2) post-COVID-LC participants refers to the LC
groups’ current characteristics and symptoms in the LC state.
The general population control group was composed of employees and their spouses from the Missouri Baptist Medical Center
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Table 1
Clinical characteristics of the study participants

Sample size (N)
Females, N (%)
Males, N (%)
Age, Mean (SD)
BMI, Mean (SD)
Race: (%)
White
Asian
Black
Native American
Hispanic
Other

Controls

Long-COVID Participants

MCAS Patients

136
89 (65.4%)
47 (34.6%)
49.2 (15.5)
25.5 (4.6)

136
122 (89.7%)
14 (10.3%)
46.9 (12.9)
28.2 (8.4)

80
68 (85.0%)
11 (13.8%)
47.7 (16.4)
25.9 (6.7)

93.3%
2.2%
2.2%
0.0%
0.0%
2.2%

88.2%
1.5%
2.9%
0.0%
0.0%
7.4%

96.3%
0%
0%
1.3%
1.3%
1.3%

MCAS patients. The prior diagnostic studies in the 80 patients
had included the following: upper endoscopy (100%), colonoscopy
(96.3%), abdominal computerized tomography (65.0%), abdominal
ultrasound (45.0%), gastric emptying study (20%), video capsule
endoscopy (11%), endoscopic retrograde cholangiopancreatography
(6.3%), and cholecystokinin-stimulated hepatobiliary iminodiacetic
acid scans (6.3%). With this work-up and a careful history and
physical examination, appropriate differential diagnoses were excluded.
MCMRS scores were calculated for each participant and ranged
from 0 to 34, with means shown in Figure 1 and Table 3.
Mean MCMRS scores for controls (9.7, SD 8.3) and pre-COVID19 LC (mean 11.4, SD 7.5) did not signiﬁcantly differ [t(267.3)=1.8, p=0.08]. Scores of LC participants increased signiﬁcantly to
21.1 (SD 6.3) after COVID-19 [t(135)=-6.1, p=0.0 0 01]. Post-COVID19 scores did not signiﬁcantly differ from those of MCAS patients prior to MCAS treatment [mean 20.1, SD 8.0; t(136.9)=0.9, p=0.4]. Mean MCMRS scores were translated into spider web
plots, with each spoke representing the mean score of symptoms affecting a different system (i.e., skin, abdomen, neurologic,
etc.). Since each system had a different maximum possible score,
they were normalized on a 0-100% scale to make each spoke the
same length. The resulting MCMRS spider web plots are shown in
Figure 3.
The MCMRS symptom count ranged from 0 to 35 among participants. As shown in Table 3, mean pre-COVID-19 symptom count
(11.6, SD 7.7) was not signiﬁcantly different from that of controls [10.2, SD 8.6; t(267.1.0)=-1.5, p=0.1]. Mean symptom count
signiﬁcantly increased after COVID to 22.0 [SD 6.6; t(135)=-16.5,
p<0.0 0 01]. This mean count did not signiﬁcantly differ from that
of MCAS patients prior to MCAS treatment [20.4, SD 8.4; t(137.4)=1.4, p=0.2].
To further investigate potential similarities between postCOVID-19 symptoms and MCAS symptoms, the MCMRS cumulative
severity score was calculated. Scores ranged from 0 to 466 among
participants. As shown in Figure 2 and Table 3, mean pre-COVID19 scores (47.2, SD 43.0) were not signiﬁcantly different from those
of controls [47.9, SD 66.6; t(231.0)=0.1, p=0.9]. The mean cumulative severity scores signiﬁcantly increased after COVID-19 [154.1,
SD 67.9; t(135)=-19.6, p<0.0 0 01]. This severity did not signiﬁcantly
differ from the severity scores of MCAS patients prior to MCAS
treatment [161.0, SD 94.3; t(127.6)=0.6, p=0.6].
Symptoms in the MCMRS were attributed to ten different bodily systems (lungs, skin, urinary/pelvic, etc.), and each participant’s
total number of affected systems was counted. Scores ranged from
0 to 10 among participants. As shown in Table 3, mean pre-COVID19-infection system count (6.1, SD 2.3) in LC participants was signiﬁcantly higher than that of controls [5.3, SD 2.8; t(261.2)=-2.5,
p=0.01]. Mean system count signiﬁcantly increased after COVID-19
infection to 8.3 [SD 1.4; t(135)=-12.3, p<0.0 0 01]. This mean count
after COVID-19 infection did not signiﬁcantly differ from that of
MCAS patients [8.0, SD 2.1; t(121.9)=-1.1, p=0.3].
Individual symptoms - from the MCMRS and other common
symptoms of MC activation or LC - were compared among the four
groups. Symptom severity ratings ranged from 0 (not present) to
10 (most severe imaginable). For each of the 51 symptoms queried
for severity, mean scores for pre-COVID-19 LC participants were
ﬁrst compared to those of controls using independent samples ttests in order to determine whether baseline symptoms recalled
by LC participants differed from those of controls. The ﬁrst two
columns of Table 4 show that baseline symptoms were not significantly different between pre-COVID-19 LC and controls for 48 of
the 51 symptoms measured. There were signiﬁcant differences for
three symptoms: controls had more chest burning/pressure/pain,
more brain fog, and less constipation than pre-COVID-19 LC participants.

Abbreviations: BMI, body mass index, kg/m2 ; MCAS, mast cell activation syndrome; N, number; SD, standard deviation.

signiﬁcant. Finally, a spider web plot was created to better display
mean MCMRS scores, with each spoke representing a system subscore (e.g., lungs, heart, skin, etc.). The system sub-scores were normalized on a scale from 0 to 100%, to make each spoke the same
length despite different maximum point values. Four spider web
plots representing mean MCMRS scores were created, one each for
general population controls, MCAS patients, pre-COVID-19 LC, and
post-COVID-19 LC.
All groups were queried as to a variety of medications and supplements. The LC group was also asked about medications and
supplements used after COVID-19 infection. Medicines and supplements included: 1) those which could speciﬁcally affect the
severity of acute COVID-19 (angiotensin converting enzyme inhibitors, carvedilol, and hydrochloroquine, ﬁve additional immune
modulators and ten different biological agents); and 2) those that
could reduce symptoms of MCA, MCAS, and/or COVID-19 (all antihistamines including H2 blockers, aspirin, benzodiazepines, montelukast, non-steroidal anti-inﬂammatory drugs, steroids, and vitamins C and D). Multivariant analysis was performed to determine
if any clinical characteristic, medicine, or supplement altered the
prevalence or severity of MCA symptoms in LC.
Results
As shown in Table 1, study participants included 136 LC participants: 89.7% females, mean age 46.9 ±12.9 years, mean BMI 28.2
±8.4 kg/m2. The 136 controls were 65.4% females, age 49.2 ±15.5,
BMI 25.5 ±4.6. The 80 MCAS patients were 85% females, age 47.7
±16.4, BMI 25.9 ±6.7. There were no signiﬁcant differences between groups in age [F(2, 349)=.84, p=0.43] or proportion of Caucasian/White participants [X2(2, N=352)=4.2, p=0.12]. The control
group had a lower percentage of females (65.4%) than the LC group
(89.7%) or MCAS group [85%; X2(2, N=351)=27.3, p<0.0 0 01]. Oneway analysis of variance with Tukey HSD post hoc analysis on BMI
showed that LC participants had signiﬁcantly higher BMI (M=28.2,
SD=8.4) than both healthy controls (M=25.5, SD=4.6) and MCAS
patients [M=25.9, SD=6.7; F(2,349)=6.04, p=0.0026]. Among LC
participants, 110 (80.9%) reported their infection was conﬁrmed by
testing, and the remainder stated that their physicians clinically diagnosed their original illness as COVID-19 without testing. Twentytwo (16.2%) LC participants reported they were hospitalized for
COVID-19 (19 diagnosed with testing and 2 clinically diagnosed).
The use of medications and supplements which can affect MC activation, COVID-19, and/or LC is summarized in Table 2.
Work-up of the MCAS patients showed a mean of 1.4 abnormal
mediators per patient: prostaglandin D2 (37.5%), histamine (33.8%),
chromogranin (33.8%), leukotriene E4 (11.8%), N-methylhistamine
(8.8%), and 2,3-dinor-11-beta-prostaglandin F2 alpha (6.3%). The
majority had gastrointestinal symptoms which is characteristic for
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Table 2
Number and percent of participants taking various medications or dietary supplements. The usage of the remainder of the medications examined was negligible.

Antihistamines
Antidepressants
Aspirin and NSAIDS
ImmunosuppressantsA
Montelukast
Vitamin C
Vitamin D
Melatonin
A
B
C
D

Controls

Pre-COVID-19 Long-COVID Patients

Post-COVID-19 Long-COVID Patients

38 (27.5%)
27 (19.6%)
54 (39.1%)
4 (2.9%)
4 (2.9%)
41 (29.7%)
66 (47.8%)
15 (10.9%)

49
24
57
10
13
54
70
20

77
24
80
40
14
89
98
50

(36.0%)
(17.6%)
(41.9%)
(7.4%)
(9.6%)B
(39.7%)
(51.5%)
(14.7%)

(56.6%)C
(17.6%)
(58.8%)C
(29.4%)C
(10.3%)
(65.4%)C
(72.1%)C
(36.8%)

MCAS Patients with MC Treatment
56 (70.0%)
19 (23.7%)
23 (28.8%)D
7 (8.7%)D
13 (16.2%)
50 (62.5%)
51 (63.7%)
9 (11.2%) D

Immunosuppressants included hydrochloroquine, ﬁve additional immune modulators and ten different biological agents.
Signiﬁcantly different from controls.
Signiﬁcantly different from pre-COVID Long-COVID.
Signiﬁcantly different from post-COVID Long-COVID.

Figure 1. Mean mast cell mediator release syndrome scores for each group, with whiskers showing 95% conﬁdence intervals.
Table 3
Mean (SD) mast cell mediator release syndrome scores (total score, cumulative severity, and system count), combined mast cell activation and
Long-COVID symptom count, fatigue, and quality of life scores.

Score, mean (SD)

Controls

Pre-COVID-19
Long-COVID Participants

Post-COVID-19
Long-COVID Participants

MCAS Patients Rating
Prior to Treatment

MCMRS
Score
MCMRS cumulative severity
MCMRS system count
MC activation and LC symptom count
Fatigue assessment scale score
Quality of life score

9.7 (8.3)
47.9 (66.6)
5.3 (2.8)
10.2 (8.6)
18.2 (7.7)
75.4 (20.2)

11.4 (7.5)
47.2 (43.0)
6.1 (2.3)A
11.6 (7.7)
16.6 (6.4)
75.6 (16.6)

21.1 (6.3)B
154.1 (67.9)B
8.3 (1.4)B
22.0 (6.6)B
34.5 (10.7)B
40.5 (21.7)B

20.1 (8.0)
161.0 (94.3)
8.0 (2.1)
20.4 (8.4)
31.2 (11.8)
56.6 (21.1)C

A

Signiﬁcantly different from controls.
Signiﬁcantly different from pre-COVID-19 Long-COVID.
C
Signiﬁcantly different from post-COVID-19 Long-COVID.Abbreviations: LC, Long-COVID; MC, mast cell; MCMRS, mast cell mediator release
syndrome; MCAS, mast cell activation syndrome; N, number; SD, standard deviation.
B
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Figure 2. Mean mast cell mediator release syndrome cumulative severity for each group, with whiskers showing 95% conﬁdence intervals.

Next, repeated measures t-tests determined whether mean
symptom severity scores increased in after COVID-19, as compared
to before COVID-19. As shown in Table 4, mean severity increased
signiﬁcantly for every symptom measured except seizures.
To determine whether post-COVID-19 symptom severity resembled that reported by MCAS patients prior to MCAS treatment, independent samples t-tests were performed for each symptom. As
shown in the last two columns of Table 4, there were signiﬁcant
differences between post-COVID-19 LC participants and MCAS patients prior to MCAS treatment for 21 of the 51 symptoms: MCAS
patients prior to MCAS treatment reported signiﬁcantly higher
severity of abdominal pain, high-histamine-content foods making
symptoms worse, nausea, abdominal pain with cramping, diarrhea,
pelvic pain, mouth inﬂammation/ulcers, ﬂushing, anal itching during attacks, hives, and skin nodules. Post-COVID-19 LC participants
reported signiﬁcantly higher severity of physical weakness doing
activities of daily living, severe fatigue attacks that makes it difﬁcult to keep eyes open, muscle pain or tenderness, chest burning/pressure/pain, cough, sweats, loss of smell, hair loss, and loss
of taste. For the other 30 symptoms, there were no signiﬁcant differences between symptom severity reported by post-COVID-19 LC
and MCAS patients prior to MCAS treatment.
Fatigue scores were calculated for each participant, with means
shown in Table 3. Pre-COVID-19 LC participant scores (mean 16.6,
SD 6.4) were not signiﬁcantly different than those of controls
[mean 18.2, SD 7.7; t(261.6)=1.8, p=0.08] but escalated significantly post-COVID-19 in LC participants [mean 34.5, SD 10.7;
t(135)=-19.8, p<0.0 0 01] to resemble those of MCAS patients prior
to MCAS treatment (mean 31.2, SD 11.8; t(113.5)=-1.9, p=0.06].
As shown in Table 3 and Figure 4 mean self-rated overall general health scores or quality of life scores were also not signiﬁ-

cantly different between pre-COVID-19 LC participants (mean 75.6,
SD 16.6) and controls [mean 75.4, SD 20.2; t(260.4)=-0.1, p=0.95).
In post-COVID-19 LC participants, these mean scores dropped signiﬁcantly to 40.5 (SD= 21.7; t(135)=16.5, p<0.0 0 01). In postCOVID-19 LC participants, these scores were signiﬁcantly lower
than those of MCAS patients prior to MCAS treatment (mean 56.6,
SD 21.1, t(118.6)=4.9, p=<0.0 0 01).

Discussion
The occurrence of MCA symptoms in LC patients has previously
not been examined in a detailed manner. In the present study,
there was a high prevalence of MCA symptoms in LC patients prior
to MCAS treatment. The symptom data and spider web plots illustrated that LC patients’ symptoms are virtually identical to those
experienced by MCAS patients. These results support, but do not
provide deﬁnitive proof of, our earlier hypothesis that LC might
often arise out of a SARS-CoV-2-driven provocation of primary or
secondary MCAS (Afrin et al., 2020a). Theories to explain promotion of MCA in LC include: 1) complex interactions of stressorinduced cytokine storms with epigenetic-variant-induced states of
genomic fragility to induce additional somatic mutations in stem
cells or other mast cell progenitors; (Afrin et al., 2020a) 2) cytokine or SARS-CoV-2 coronavirus activation of mast cells and microglia; (Theoharides and Conti, 2020) 3) dysregulation of genes
by SARS-CoV-2 coronavirus leading to loss of genetic regulation
of mast cells; (Maxwell et al., 2021) 4) development of autoantibodies which react with immunoglobulin receptors on mast cells;
(Liu et al., 2021, Vojdani et al., 2021) and 5) increase in Toll-like
receptor activity by the coronavirus (Mukherjee et al., 2021).
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Figure 3. Spider web plots of mean mast cell mediator release syndrome scores.

When major stressors drive escalations of MCAS, those escalations tend to be sustained for long/indeﬁnite periods and sometimes clearly are permanent. This is likely due to complex interactions between epigenetic and genetic aberrancies and the stressor’s
induced cytokine storm, inducing additional mutations in the stem
cells giving rise to the aberrant mast cells (Altmüller et al., 2017;
Haenisch et al., 2012; Haenisch et al., 2014; Molderings et al., 2007,
Molderings et al., 2010, Molderings, 2015, Molderings, 2016). In a
similar fashion, post-infectious chronic multisystem inﬂammatory
syndromes are suspected to be rooted in initiation of mutations
of normal stem cells leading to aberrant controller genes (e.g.,
Epstein-Barr virus and tick-borne infections) (Afrin et al., 2016a,
Kempuraj et al., 2020, Talkington and Nickell, 1999).
Potential limitations of our study include gender recruitment
imbalance. LC females outnumbered LC males. This is likely due
to the makeup of the LC Facebook group and/or gender preference for recruitment. In a concurrent study to ours with a similar design/methodology, 78.9% of 3762 LC Internet responders were
women (Davis et al., 2021). In the largest study to date, LC was
more common in women (FAIR Health White Paper, 2021). With
respect to gender imbalance in the general population control, it is
likely that more women than men were recruited because of gen-

der imbalance of employees at the hospital and endoscopy center
and these individuals may not have recruited male spouses. In our
studies and clinical practices, we have observed that MCAS patients
have a signiﬁcantly higher percentage of women (Afrin et al., 2017,
Molderings et al., 2013). We recognize that members of most social media groups are largely self-selected and do not constitute
a randomly selected population and may not necessarily represent
the general population of patients who have LC. Subjects who join
a medical support group might be more ill than other patients.
Yet, examination of such groups may provide preliminary insights
which may provide useful guidance for further research. The fact
that the MCAS patients were diagnosed at a gastroenterology clinic
that subspecializes in MCAS could have biased the comparison
group by having increased severity of gastrointestinal symptoms.
Nonetheless, MCAS patients often present to gastroenterologists as
well as many other specialists (e.g., allergists, cardiologists, neurologists, and urologists) (Weinstock et al., 2021). Retrospective data
entered by the MCAS patients was not ideal methodology. Their
symptoms, however, were experienced within a 2-year period of
the study and MCAS symptoms often are present for decades. Another potential problem is that the LC group completed their preCOVID-19 questionnaire by recall, and thus this part of the study
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Table 4
Mean (SD) symptom severity with a range of 0 to 10 in the three groups of participants.

Symptoms

Controls

Pre-COVID-19
Long-COVID Patients

Post-COVID-19
Long-COVID Patients

Physical weakness doing ADL
Brain fog
Fatigue attacks with diﬃculty keeping eyes open
Rapid heart rate
Muscle pain or tenderness
Sleep deprivation worsens symptoms
Shortness of breath
Migraines
Nerve discomfort in legs or arms
Chest burning, pressure, or pain
Joint pain
Sudden dizziness
Itching or burning eyes
Runny or stuffy nose
Dry eyes
Ears have ringing or odd sounds
Chills
Dry mouth
Abdominal pain
Histamine foods worsen symptoms
ConstipationE
Cough
Easy bruising
Sweats
Nausea
Hot ﬂashes
Fasting worsens symptoms
Abdominal pain with cramping
VertigoE
Loss of smellF
Loss of hairE , F
Diarrhea
Loss of tasteF
Pelvic Pain
Wheezing
Flushing
Bone pain
Weight loss
Heavy menstrual bleeding
Rashes
Abdominal pain with burning
Mouth inﬂammation or ulcers
Hemangiomas
Fever
Hives
Face swelling during attacks
Skin lesions
Anal itching during attacks
Skin nodules
Unusual nasal bleeding
Seizures

1.3
1.9
1.0
1.2
1.7
1.8
0.8
1.5
1.4
0.8
2.1
1.2
1.6
2.0
1.4
1.5
0.8
0.8
1.5
1.1
1.1
1.0
1.7
0.7
1.0
0.7
0.8
1.3
0.8
0.0
0.4
1.0
0.0
0.8
0.7
0.6
0.6
0.6
1.1
0.5
0.5
0.6
0.8
0.1
0.5
0.2
0.2
0.3
0.2
0.4
0.1

1.5
1.2
0.8
0.7
1.6
1.6
0.7
1.9
0.9
0.4
1.7
1.0
1.6
1.6
1.5
1.3
0.5
1.0
1.4
1.0
1.9
0.7
1.9
0.9
0.6
0.8
0.7
1.2
0.6
0.1
0.4
1.1
0.0
1.0
0.7
0.9
0.6
0.6
1.8
0.7
0.5
0.5
1.0
0.2
0.5
0.3
0.2
0.3
0.2
0.3
0.1

6.8
6.0
5.5
5.1
5.0
4.8
4.7
4.6
4.5
4.2
4.1
4.0
3.9
3.8
3.4
3.3
3.3
3.2
3.2
3.2
3.1
3.1
3.1
3.0
3.0
2.9
2.8
2.7
2.7
2.6
2.5
2.5
2.4
2.4
2.3
2.2
2.2
1.9
2.1
1.9
1.8
1.8
1.5
1.5
1.3
1.1
0.7
0.6
0.6
0.6
0.1

(2.1)
(2.5)
(1.8)
(2.2)
(2.4)
(2.5)
(1.9)
(2.8)
(2.6)
(2.0)
(2.8)
(2.3)
(2.4)
(2.4)
(2.2)
(2.4)
(1.9)
(2.0)
(2.3)
(2.1)
(2.2)
(1.9)
(2.4)
(1.7)
(2.2)
(2.0)
(1.8)
(2.4)
(1.8)
(0.3)
(1.3)
(2.2)
(0.3)
(2.0)
(1.6)
(1.4)
(1.5)
(1.7)
(2.3)
(1.4)
(1.4)
(1.8)
(1.8)
(0.5)
(1.5)
(.8)
(1.0)
(1.5)
(0.7)
(1.3)
(0.9)

(1.9)
(1.9)A
(1.5)
(1.6)
(2.2)
(2.4)
(1.3)
(2.7)
(1.8)
(0.9)A
(2.3)
(1.7)
(2.3)
(1.9)
(2.1)
(2.3)
(1.3)
(1.8)
(1.9)
(1.7)
(2.7)A
(1.5)
(2.3)
(1.7)
(1.2)
(1.7)
(1.6)
(2.1)
(1.4)
(0.6)
(1.0)
(1.9)
(0.4)
(1.8)
(1.4)
(1.8)
(1.6)
(1.4)
(2.7)
(1.0)
(1.4)
(1.3)
(1.8)
(0.6)
(1.3)
(.9)
(0.9)
(1.6)
(0.9)
(1.0)
(0.5)

(2.3)B
(2.8)B
(3.1)B
(3.2)B
(3.1) B
(3.4)B
(2.9)B
(3.3)B
(3.3)B
(3.0)B
(3.2)B
(2.9)B
(3.2)B
(3.0)B
(3.2)B
(3.3)B
(2.8)B
(3.1)B
(3.0)B
(3.3)B
(3.2)B
(3.0)B
(2.8)B
(2.9)B
(2.9)B
(3.0)B
(3.1)B
(2.8)B
(3.0)B
(3.2)B
(3.1)B
(3.0)B
(3.2)B
(3.0)B
(3.0)B
(2.9)B
(2.8)B
(2.9)B
(3.2)
(2.7)B
(2.7)B
(2.6)B
(2.3)B
(2.2)B
(2.4)B
(2.2)B
(1.7)B
(1.6)B
(1.6)B
(1.5)B
(0.5)

MCAS Patients Rating
Prior to Treatment
5.7
5.2
4.4
4.3
4.0
4.4
4.0
4.7
4.7
3.3
3.8
4.3
4.2
4.3
2.6
3.9
2.7
2.4
4.9
5.4
3.2
1.9
3.4
2.0
4.6
3.5
3.4
4.8
2.1
0.4
1.3
4.2
0.3
3.8
1.9
3.8
2.9
1.8
2.3
2.2
2.2
2.9
1.9
0.6
2.9
1.6
1.4
1.9
1.3
0.9
0.2

(3.1)C
(3.6)
(3.6)C
(3.2)
(3.7) C
(4.1)
(3.3)
(4.0)
(3.6)
(3.3)C
(3.6)
(3.7)
(3.4)
(3.3)
(3.5)
(3.7)
(3.3)
(3.6)
(3.5)C
(3.6)C
(3.8)
(2.6)C
(3.1)
(3.1)C
(3.7)C
(3.7)
(4.0)
(3.6)C
(3.3)
(1.4)C
(2.6)C
(3.7)C
(1.3)C
(3.9)C
(2.9)
(3.7)C
(3.6)
(3.0)
(3.5
(2.9)
(3.6)
(3.4)C
(3.0)
(1.8)C
(3.5)C
(2.9)
(2.7)
(3.1)C
(2.4)C
(2.1)
(1.1)

A

Pre-COVID-19 Long-COVID mean is signiﬁcantly different from controls.
Post-COVID-19 Long-COVID mean is signiﬁcantly different from pre-COVID-19 Long-COVID.
C
MCAS patients’ mean is signiﬁcantly different from post-COVID-19 Long-COVID.
E
Common symptom in MCAS patients but not included in the standard MCMRS questionnaire.
F
Common symptom in Long-COVID.Abbreviations: ADL, activity of daily living; MCAS, mast cell activation syndrome; MCMRS, mast cell mediator release syndrome.
B

was retrospective. This was a limitation of the study design, yet the
spider symptom/severity plots at baseline were remarkably similar
to the general population control group, likely negating this issue.
In this study, symptoms suggesting new MCA were signiﬁcantly
increased in LC. Although the symptoms that LC share with MCAS
patients are similar, we are not equating LC with a mutual diagnosis of MCAS since diagnosis of MCAS compliant with published
criteria requires testing not pursued in the LC participants. Furthermore, MCA symptoms can be present purely due to normal reactivity to various stimuli by normal MCs and may fade as the MC
activation-driving stimulus resolves. At present, detection of somatic mutations in mast cells is not available in any clinical labo-

ratories and thus it is not possible to prove whether any given case
of LC is primary vs. secondary MCAS. A number of small trials have
found beneﬁt from MC-stabilizing drugs in acute COVID-19 and LC
(Kazama, 2020). We have seen improvement in our LC patients in
our clinics (LBW, LBA) using a varying combination of MC-directed
therapies including antihistamines, cromolyn, ﬂavonoids (quercetin
and lutein), low dose naltrexone, montelukast, and vitamins C
and D (Barré et al., 2020, Choubey et al., 2020, Colunga Biancatelli et al., 2020, Freedberg et al., 2020, Gigante et al., 2020,
Hogan et al., 2020, Janowitz et al., 2020, Mather et al., 2020,
Patterson et al., 2021, Pinheiro et al., 2021, Theoharides, 2020,
Theoharides et al, 2021, Weng et al, 2015). Low dose naltrexone
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Figure 4. Changes in Long-COVID participants mean symptom severity scores before and after COVID-19 (all are statistically different; p<0.05).

has also been used to treat MCAS and may be effective in LongCOVID, possibly by reducing cytokines from T-cells which activate
mast cells and by blocking Toll-like receptors on mast cells and microglia (Mukherjee et al., 2021, Weinstock and Blasingame, 2020).

roles in LC (Koupenova and Freedman, 2020, Maxwell et al., 2021,
Perricone et al., 2020). Our observations may lead to effective therapy for those suffering from LC. Further studies of LC patients
with measurements of MC mediators and clinical trials using MCdirected medications are warranted.

Conclusion
In this study, MCA symptoms were signiﬁcantly increased in
LC. Uncontrolled, aberrant mast cells may in part underlie the
pathophysiology of LC. Inﬂammation caused by COVID-19 is complicated, and other immune disturbances that have been seen in
the acute infection such as excess dysfunction of the macrophage
and serotonin release from platelets might or might not play
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